You waited for the clearance letter. Now it has arrived. The instinct is to go immediately to market with everything you have been holding back. That instinct is mostly right, but the transition from pre-clearance to commercial launch requires a specific sequence that most device companies get wrong because they treat the clearance letter as permission to say anything and everything, rather than as a precise document that defines exactly what they may say.
Here is how the first 90 days should run.
Before You Launch Anything: Read the Clearance Letter
Your 510(k) substantial equivalence order is not a generic document. It specifies the exact indications for use, the intended patient population, the use environment, and sometimes specific conditions or limitations. Every marketing claim you make for the next 90 days, and beyond, will be evaluated against what that document says.
Specifically, locate and copy out the indications-for-use statement. That statement is the legal boundary of what you may promote. If your clearance letter limits the device to "long-term monitoring of arrhythmia events for non-critical care patients where real-time monitoring is not needed," you may not promote it for high-acuity monitoring or for patient populations not described in the clearance. This is one of the patterns cited in the FDA's May 25, 2023 warning letter to iRhythm Technologies. iRhythm's Zio QX ECG Monitoring System was cleared under K163512 for long-term monitoring of non-critical care patients where real-time monitoring is not needed. According to the warning letter, the company's Zio AT marketing materials and website described the device as a "mobile cardiac telemetry monitor" intended for "near real-time monitoring" and "high-risk patients," which the FDA determined described a new patient population that required a new 510(k). (That letter also cited separate device changes made without a new 510(k), plus medical device reporting and quality system violations, so it is not solely a promotion case.) (See the FDA warning letter at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/irhythm-technologies-inc-643474-05252023.)
The clearance letter review is not a one-time event. It should become a standing step in your content review process so that every piece of sales and marketing material is evaluated against the cleared indications before publication.
Days 1 to 14: Claims Alignment and Copy Audit
The first two weeks are internal. No external announcements yet. This window is for getting your copy right before it reaches anyone.
Step 1: Pull every piece of pre-clearance content
Every web page, sales deck, data sheet, trade show panel, investor presentation, LinkedIn post, and brochure that touched your product must be reviewed and updated to reflect your actual cleared status.
Changes to make throughout:
- Replace any pending-clearance language with accurate cleared language. ("510(k) cleared" or "FDA cleared," never "FDA approved.")
- Update indications-for-use language to match the clearance letter exactly. Not your pre-submission version. The letter.
- Add the 510(k) number. The FDA assigns a K-number upon clearance (e.g., K231234). Including it in your marketing materials is not required, but many device companies include it as a transparency signal and it is useful for procurement professionals who will look up the clearance.
- Remove any forward-looking regulatory language ("clearance expected in Q3," "pending FDA review").
Step 2: Establish claims ownership
Assign someone, ideally your regulatory affairs lead, as the approver for all marketing claims going forward. Define the process: every new marketing claim is checked against the cleared indications before publication. No exceptions.
Step 3: Build the claims matrix
Create a one-page internal reference document listing your cleared indications, the patient population, the intended use environment, and any specific limitations noted in the clearance letter. This becomes the filter through which every marketing, sales, and communications piece passes.
Days 15 to 30: Digital and PR Launch
With claims alignment done, the external-facing work begins.
Website update
The product pages on your website were likely placeholders or carefully hedged pre-clearance copy. Now they become full commercial pages. A compliant post-clearance product page includes:
- The accurate regulatory status ("FDA cleared") and the specific cleared indications for use, in plain language.
- Technical specifications, if relevant to buyer decisions.
- Supporting clinical data, described accurately and within the scope of your cleared intended use.
- No superlatives or comparative superiority claims unless you have head-to-head data to support them (see the warning on unsubstantiated superiority claims in this cluster's companion article on marketing claims).
Press release: clearance announcement
A clearance announcement press release is standard practice and expected by investors, distributors, and potential customers. A compliant clearance press release:
- States the clearance accurately ("received 510(k) clearance from the U.S. Food and Drug Administration").
- Describes the cleared indication for use precisely.
- Does not use "FDA approved" for a 510(k) outcome.
- Does not claim market leadership, superiority, or effectiveness beyond what the cleared data supports.
- Includes a factual quote from a company executive. Does not use unsourced testimonials or projected patient outcome claims.
Distribute via wire service and to your targeted trade press (medical device trade publications, clinical association newsletters relevant to your indication, health system procurement newsletters).
Update regulatory database entries
The FDA's 510(k) database (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm) will reflect your clearance, but third-party databases, your own product registration filings, and any submission to group purchasing organizations (GPOs) need to be updated with your K-number and cleared indications.
Begin LinkedIn and digital channel activation
Your company LinkedIn page, executive profiles, and any paid search or social campaigns should now reflect cleared status. LinkedIn posts announcing the clearance are appropriate and expected. Keep the language accurate: "510(k) cleared" or "FDA cleared," the date, and the indication. If you have a KOL or clinical advisor who has been involved and wishes to comment, their post should similarly use accurate regulatory language.
Days 31 to 60: Sales Enablement and KOL Activation
Sales team training
Your sales team is about to enter conversations with procurement officers, clinical directors, value analysis committees, and clinicians. They need to know the following before those conversations happen:
- The exact cleared indications for use, and the exact language they may use to describe them.
- What they may not say: any claimed benefit, patient population, or clinical scenario not covered by the clearance. Off-label promotion by sales representatives carries the same regulatory risk as off-label promotion in advertising.
- How to answer the question "is this FDA approved?" with an accurate response ("This device is FDA cleared, which means it received a 510(k) substantial equivalence determination. Here is our clearance letter.")
Sales training on regulatory language is not optional and is not covered by most generic sales onboarding programs. Your regulatory team should own this training and conduct it before commercial conversations begin.
Sales collateral audit
Every piece of collateral your sales team carries, physical or digital, should be reviewed against the cleared indications. This includes sell sheets, ordering information, reimbursement guides, and any clinical case studies. If a case study describes an off-label use, even anecdotally, it should not be in the sales kit.
Key Opinion Leader (KOL) activation
Clinical KOLs who have been involved in your IDE trial or development process can now speak publicly about their experience with the device. Compliant KOL activation:
- KOL commentary should be within the cleared indications. A KOL speaking about an off-label use in a sponsored context is the same regulatory risk as the company making the claim.
- Written agreements with KOLs should specify that any promotional speaking or content must remain within cleared indications.
- Any KOL-authored content on company channels is considered company promotional material for FDA purposes. Apply the same claims review process.
Days 61 to 90: Conference and Ecosystem Integration
Trade conference and medical meeting strategy
Medical conferences are your highest-value channel for reaching clinicians and procurement decision-makers. Post-clearance conference strategy includes:
- Exhibit floor presence with compliant materials. Every sign, handout, and demonstration must stay within cleared indications.
- Symposia and speaking presentations. If you sponsor a symposium, the content must be within cleared indications. An FDA-cleared device marketed as being appropriate for patients not covered by its clearance, in a sponsored symposium, creates the same risk as any other off-label promotional activity.
- Abstracts and podium presentations by clinicians. Scientific presentations by independent investigators are different from company-sponsored promotional content. The boundary can blur when the company is heavily involved in the presentation content. Your regulatory counsel should advise on the specific fact pattern.
GPO and IDN contract applications
Group purchasing organizations and integrated delivery networks have their own evaluation processes. Your K-number and cleared indications will be required. Provide them accurately. Do not expand claimed indications in purchasing forms in ways that exceed your clearance.
Reimbursement navigation
If your device has an existing CPT or HCPCS code applicable to its indication, your launch materials can reference reimbursement guidance. If reimbursement is uncertain or pending, say so accurately. Do not imply covered status that has not been established.
The Claims Consistency Principle
Everything in this playbook depends on one underlying discipline: every claim you make publicly, in any channel, must be consistent with your cleared indications for use. The FDA's enforcement posture is not limited to advertising. A sales representative's conversation, a KOL's sponsored presentation, a LinkedIn comment by your CEO, and a case study on your website are all promotional materials for purposes of FDA oversight.
The enforcement record shows what happens when this consistency breaks down. Two 2023 warning letters illustrate the pattern. In its May 25, 2023 letter to iRhythm Technologies, the FDA cited (among other issues) marketing of the Zio AT for near real-time monitoring of high-risk patients, a new patient population beyond what the Zio QX clearance under K163512 supported. In its July 5, 2023 letter to Outset Medical, the FDA cited promotion of the Tablo Hemodialysis System for continuous renal replacement therapy (CRRT), a use outside the device's cleared indications under K223248. Clearance does not give unlimited claims authority. It gives carefully bounded claims authority, and that boundary is your indications-for-use statement.
A Practical Note on Marketing Infrastructure
Most device companies build their marketing infrastructure after clearance, which means they lose six to twelve months of potential market momentum. Companies that invest in building compliant content, audience, and digital presence in the pre-clearance period arrive at launch day with an audience that already understands the clinical problem, a website that has accumulated domain authority, and a list of interested prospects to contact on day one. (For where that line sits before you clear, see the companion article Can You Market a Medical Device Before FDA Clearance?)
Buzzbox Media works exclusively with medical device and healthcare companies. Our launch programs include a regulatory claims review step so that what goes out the door has been evaluated against your cleared indications before it reaches a prospect. If you are preparing for a clearance in the next six to twelve months, that is the right time to start building. Learn more about our medical device marketing services or book a 30-minute call at https://www.buzzboxmedia.com/book.
Related Reading in This Series
- Can You Market a Medical Device Before FDA Clearance?
- FDA Cleared vs FDA Approved: What You Can Legally Say in Your Medical Device Marketing
- Medical Device Marketing Claims the FDA Allows (and the Ones That Trigger Warning Letters)
- De Novo and PMA Launch Marketing: What You Can and Cannot Say
Frequently Asked Questions
See the full FAQ below.
Sources Cited
- 21 CFR 807.97 (Misbranding by reference to premarket notification): https://www.law.cornell.edu/cfr/text/21/807.97
- 21 U.S.C. 352 (FD&C Act Section 502, misbranded devices): https://uscode.house.gov/view.xhtml?req=(title:21+section:352+edition:prelim)
- FDA, Premarket Notification 510(k): https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
- FDA, 510(k) Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
- FDA, General Device Labeling Requirements: https://www.fda.gov/medical-devices/device-labeling/general-device-labeling-requirements
- FDA, Warning Letter: iRhythm Technologies, Inc. #643474, May 25, 2023: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/irhythm-technologies-inc-643474-05252023
- FDA, Warning Letter: Outset Medical, Inc. #656485, July 5, 2023: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/outset-medical-inc-656485-07052023
- FTC, Disclosures 101 for Social Media Influencers: https://www.ftc.gov/business-guidance/resources/disclosures-101-social-media-influencers
- FDA, How to Study and Market Your Device: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/how-study-and-market-your-device